Home>URGO has obtained €11.7 million through the French Government’s « Investing for the Future » scheme for supporting the development of treatment for diabetic foot ulcer

30 September 2016

URGO has obtained €11.7 million through the French Government’s « Investing for the Future » scheme for supporting the development of treatment for diabetic foot ulcer

URGO Group is receiving funding of €11.7 million from the « Investing for the Future » programme (PIA) through the call for projects from the PIAVE (« Projets Industriels d’Avenir », or « Industrial Projects for the Future ») scheme, steered by the Commissariat Général à l’Investissement (CGI), and operated by Bpifrance. This funding is earmarked for developing the Akeome project that should enable Urgo Medical, the advanced wound healing division of the URGO Group, to become one of the world leaders in advanced wound healing, by meeting an unsatisfied medical need in the treatment of diabetic foot ulcer.

Akeome, a treatment for improving diabetic foot care

The number of people suffering from diabetes is ever-increasing, and 15% of those sufferers will develop foot ulceration during their lives , that pathology affecting developing countries as much as it does developed countries, like the United States.
Faced with this major issue for public health, it is the ambition of URGO’s Akeome to improve the treatment for this pathology by means of a new local treatment that combines an active pharmaceutical with a patented healing matrix.

Through the financial support from the public authorities, Urgo Medical will thus conduct the clinical trials required for obtaining the marketing authorisations, including a programme of clinical trials in Europe and in the United States, essential for accessing the international market, and more specifically the American market, will industrially develop Akeome in France, and will then market and sell it through its subsidiaries and strategic partners present throughout the world. The financial support is going to enable the URGO Group to progress through several stages on this market segment for diabetic foot that is worth 2.8 billion dollars, 1/3 of which is accounted for by the United States. The annual cost of treating diabetes complications on the lower limbs is estimated at 17 billion dollars in the United States.

An opportunity for creating jobs in France, at our Dijon site

With industrial production being located in France, the project to develop Akeome will make it possible to support job creation, in particular for jobs in R&D, industrial transposition, production, and sales.

This funding will enable URGO, who has internal expertise in wound healing, to succeed on the segment of diabetic foot ulcer, to access the US market, and to position itself as a key player on the global advanced wound care market.

Pierre Moustial, Managing Director of the URGO Group, declared: « We are very proud that our project to develop diabetic food ulcer treatment is one of the projects of the « New Industrial France », the French Government’s scheme to reindustrialise France. This recognition from the Commissariat Général à l’Investissement and from Bpifrance confirms URGO’s capacity for technological and industrial innovation to improve the lives of patients, by developing a treatment for this serious and costly pathology that affects 15% of the 366 million diabetes patients across the world. »

Share this article

sur twitter sur linkedin on facebook by mail

print this article :

print